CERS - Cerus raises guidance ahead of consensus after strong revenue beat

Cerus Corporation (NASDAQ:CERS) has added ~17.2% in the post-market after the company exceeded analyst expectations for revenue by as much as ~$10.5M with its Q3 2021. The maker of INTERCEPT Blood System also set its 2021 guidance ahead of Street forecasts. “Cerus’ third quarter results represent a strong commercial achievement for the Company, in particular with regard to the U.S. platelet business,” CEO William ‘Obi’ Greenman noted. Driven by increased sales of INTERCEPT platelet products to U.S. blood centers, the product revenue for the quarter jumped ~53% YoY to ~$36.1M expanding total revenue ~44% YoY to $42.1M. Platelet Kits growth in the U.S. stood at ~168% YoY compared to ~5% YoY rise internationally. The calculated number of treatable platelet doses expanded ~162% YoY domestically compared to ~5% YoY internationally. Net loss attributable to Cerus (CERS) dropped ~12% YoY to $12.4M while R&D expenses slipped ~4% YoY to $36.1M. For 2021, the company

For further details see:

Cerus raises guidance ahead of consensus after strong revenue beat